Journey Medical Stock Earnings Reports

Journey Medical reported strong Q1 2026 results driven primarily by Emrosi, with total net product revenues up 21% year-over-year to $16.0 million and Emrosi sales of $6.3 million (up materially vs. prior year). Emrosi prescriptions grew to ~30,000 (11% sequential growth) and unique prescribers rose to ~3,700, with refill-to-new prescription ratio improving toward ~1.5:1 — indicating growing patient retention. Management highlighted improving payer coverage momentum after securing contracts with all three major PBM-affiliated GPOs (increasing theoretical commercial access to ~169M lives), ongoing downstream plan negotiations focused on quality of coverage (tiering, prior auths, step edits), and plans to add up to five sales reps and potentially launch up to two niche dermatology products later in 2026. Gross margin was 61% (would be ~69% ex a $1.3M noncash API write-down); GAAP net loss narrowed to $2.2M; adjusted EBITDA was positive $0.6M. Cash increased to $27.2M. Management reiterated expectations for continued operating leverage and stated confidence that the company will deliver positive adjusted EBITDA and generate positive EBITDA for the remainder of the year as Emrosi reimbursement and prescription conversion improve.